open access

Vol 78, No 6 (2010)
Published online: 2010-10-29
Submitted: 2013-02-22
Get Citation

Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma

Jacek Jassem, Wojciech Biernat, Kazimierz Drosik, Rafał Dziadziuszko, Radzisław Kordek, Jerzy Kozielski, Dariusz M. Kowalski, Maciej Krzakowski, Jacek Nikliński, Włodzimierz Olszewski, Tadeusz Orłowski, Rodryg Ramlau, Kazimierz Roszkowski-Śliż, Witold Rzyman
Pneumonol Alergol Pol 2010;78(6):418-431.

open access

Vol 78, No 6 (2010)
Published online: 2010-10-29
Submitted: 2013-02-22


Not available


Not available
Get Citation
About this article

Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma


Advances in Respiratory Medicine


Vol 78, No 6 (2010)



Published online


Bibliographic record

Pneumonol Alergol Pol 2010;78(6):418-431.


Jacek Jassem
Wojciech Biernat
Kazimierz Drosik
Rafał Dziadziuszko
Radzisław Kordek
Jerzy Kozielski
Dariusz M. Kowalski
Maciej Krzakowski
Jacek Nikliński
Włodzimierz Olszewski
Tadeusz Orłowski
Rodryg Ramlau
Kazimierz Roszkowski-Śliż
Witold Rzyman

References (204)
  1. Buist AS, McBurnie MA, Vollmer WM, et al. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370(9589): 741–750.
  2. Loddenkemper R. European Lung White Book. The first comprehensive survey on respiratory health in Europe. ERS 2003.
  3. Pływaczewski R, Maciejewski J, Bednarek M, et al. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008; 63(5): 402–440.
  4. Nizankowska-Mogilnicka E, Mejza F, Buist AS, et al. Prevalence of COPD and tobacco smoking in Malopolska region--results from the BOLD study in Poland. Pol Arch Med Wewn. 2007; 117(9): 402–410.
  5. ECAP. Samoliński B. (red.). Epidemiologia chorób alergicznych w Polsce.
  6. Didkowska J, Wojciechowska U, Tarnowski W. Nowotwory złośliwe w Polsce w 2006 roku. Centrum Onkologii-Instytut im. M. Skłodowskiej-Curie, Warszawa 2008.
  7. Korzeniewska-Koseła M. Gruźlica i choroby układu oddechowego w Polsce w 2009 roku. Instytut Gruźlicy i Chorób Płuc, Warszawa 2009.
  8. Muers MF, Round CE. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax. 1993; 48(4): 339–343.
  9. Sawicki GS, Sellers DE, Robinson WM. Self-reported physical and psychological symptom burden in adults with cystic fibrosis. J Pain Symptom Manage. 2008; 35(4): 372–380.
  10. Walke LM, Byers AL, Tinetti ME, et al. Range and severity of symptoms over time among older adults with chronic obstructive pulmonary disease and heart failure. Arch Intern Med. 2007; 164: 2321–2324.
  11. Burgel PR, Nesme-Meyer P, Chanez P, et al. Initiatives Bronchopneumopathie Chronique Obstructive Scientific Committee. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009; 135(4): 975–982.
  12. Goldbeck L, Besier T, Hinz A, et al. TIDES Group. Prevalence of symptoms of anxiety and depression in German patients with cystic fibrosis. Chest. 2010; 138(4): 929–936.
  13. Boulet LP, Phillips R, O'Byrne P, et al. Evaluation of asthma control by physicians and patients: comparison with current guidelines. Can Respir J. 2002; 9(6): 417–423.
  14. King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 2006; 100(12): 2183–2189.
  15. Ryu YJu, Chun EM, Lee JH, et al. Prevalence of depression and anxiety in outpatients with chronic airway lung disease. Korean J Intern Med. 2010; 25(1): 51–57.
  16. Sepúlveda C, Marlin A, Yoshida T, et al. Palliative Care: the World Health Organization's global perspective. J Pain Symptom Manage. 2002; 24(2): 91–96.
  18. Griffin JP, Koch KA, Nelson JE, et al. American College of Chest Physicians. Palliative care consultation, quality-of-life measurements, and bereavement for end-of-life care in patients with lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132(3 Suppl): 404S–422S.
  19. Buczkowski K, Krajnik M. Opieka paliatywna. Wydawnictwo Lekarskie PZWL, Warszawa 2009.
  20. Murray SA, Kendall M, Boyd K, et al. Illness trajectories and palliative care. BMJ. 2005; 330(7498): 1007–1011.
  21. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60(11): 925–931.
  22. Eriksen N, Vestbo J. Management and survival of patients admitted with an exacerbation of COPD: comparison of two Danish patient cohorts. Clin Respir J. 2010; 4(4): 208–214.
  23. Budweiser S, Hitzl AP, Jörres RA, et al. Health-related quality of life and long-term prognosis in chronic hypercapnic respiratory failure: a prospective survival analysis. Respir Res. 2007; 8: 92.
  24. Budweiser S, Jörres RA, Riedl T, et al. Predictors of survival in COPD patients with chronic hypercapnic respiratory failure receiving noninvasive home ventilation. Chest. 2007; 131(6): 1650–1658.
  26. Gaga M, Papageorgiou N, Yiourgioti G, et al. ENFUMOSA Study Group. Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire. Clin Exp Allergy. 2005; 35(7): 954–959.
  27. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One. 2007; 2(5): e482.
  28. Mackay LS, Anderson RL, Parry G, et al. Pulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation. Thorax. 2007; 62(12): 1069–1073.
  29. Ley B, Swigris J, Day BM, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007; 176(7): 636–643.
  30. Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006; 27(1): 143–150.
  31. Park IN, Jegal Y, Kim DS, et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J. 2009; 33(1): 68–76.
  32. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003; 168(5): 531–537.
  33. Ryu JH, Myers JL, Capizzi SA, et al. Desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease. Chest. 2005; 127(1): 178–184.
  34. Grutters JC, Wells AU, Wuyts W, et al. Evaluation and treatment of interstitial lung involvement in connective tissue diseases: a clinical update. Pulmonary Manifestations of Systemic Diseases. 2005: 27–49.
  35. Cordier J. F. Organizing pneumonia: cryptogenic and disease associated. Semin. Respir. Crit. Care Med. 2003; 24: 595–603.
  36. Silva CI, Müller NL, Lynch DA, et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology. 2008; 246(1): 288–297.
  37. Katzenstein ALA, Mukhopadhyay S, Myers JL. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum Pathol. 2008; 39(9): 1275–1294.
  38. Olson AL, Huie TJ, Groshong SD, et al. Acute exacerbations of fibrotic hypersensitivity pneumonitis: a case series. Chest. 2008; 134(4): 844–850.
  39. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007; 357(21): 2153–2165.
  40. Walsh TJ, Anaissie EJ, Denning DW, et al. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(3): 327–360.
  41. Vassallo R, Ryu JH, Schroeder DR, et al. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med. 2002; 346(7): 484–490.
  42. Ryu JH, Moss J, Beck GJ, et al. NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006; 173(1): 105–111.
  43. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002; 166(2): 215–235.
  44. Zamora AC, Collard HR, Wolters PJ, et al. Neurofibromatosis-associated lung disease: a case series and literature review. Eur Respir J. 2007; 29(1): 210–214.
  45. Mariotta S, Ricci A, Papale M, et al. Pulmonary alveolar microlithiasis: report on 576 cases published in the literature. Sarcoidosis Vasc Diffuse Lung Dis. 2004; 21(3): 173–181.
  46. Chan ED, Strand MJ, Iseman MD. Multidrug resistant tuberculosis (TB) resistant to fluorochinolones and streptomycin but susceptibility to second-line injection therapy has a better prognosis than extensively drug-resistant TB. CID. 2009; 48: e50–52.
  47. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J. 2009; 33(5): 1085–1094.
  48. Griffith DE, Aksamit T, Brown-Elliott BA, et al. ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175(4): 367–416.
  49. Dodge JA, Morison S, Lewis PA, et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child. 1997; 77(6): 493–496.
  50. McCormick J, Sims EJ, Green MW, et al. Comparative analysis of Cystic Fibrosis Registry data from the UK with USA, France and Australasia. J Cyst Fibros. 2005; 4(2): 115–122.
  51. Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J. 2007; 29(3): 522–526.
  52. Conlan AA, Hurwitz SS, Krige L, et al. Massive hemoptysis. Review of 123 cases. J Thorac Cardiovasc Surg. 1983; 85(1): 120–124.
  53. Didkowska J, Wojciechowska U, Tarnowski W. Nowotwory złośliwe w Polsce w 2006 roku. Centrum Onkologii-Insytut im M Skłodowskiej-Curie, Warszawa 2008.
  54. Naruke T, Goya T, Tsuchiya R, et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988; 96(3): 440–447.
  55. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006; 28(3): 523–532.
  56. Batura-Gabryel H. Zmiany ogólnoustrojowe u chorych na przewlekłą obturacyjną chorobę płuc. Pneumonol Alergol Pol. 2009; 77: 180–185.
  57. Potter J, Hami F, Bryan T, et al. Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med. 2003; 17(4): 310–314.
  58. Dudgeon DJ, Kristjanson L, Sloan JA, et al. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manage. 2001; 21(2): 95–102.
  60. Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med. 2008; 19(4): 227–235.
  61. Walters JAE, Tan DJ, White CJ, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014(9): CD001288.
  62. Navigante AH, Cerchietti LCA, Castro MA, et al. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage. 2006; 31(1): 38–47.
  63. Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2010; 10(1): CD007354.
  64. Jennings AL, Davies AN, Higgins JPT, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002; 57(11): 939–944.
  65. Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011; 42(3): 388–399.
  66. Rocker G, Horton R, Currow D, et al. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax. 2009; 64(10): 910–915.
  67. Larkin PJ, Sykes NP, Centeno C, et al. European Consensus Group on Constipation in Palliative Care. The management of constipation in palliative care: clinical practice recommendations. Palliat Med. 2008; 22(7): 796–807.
  68. Bruera E, Sala R, Spruyt O, et al. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage. 2005; 29(6): 613–618.
  69. Galbraith S, Fagan P, Perkins P, et al. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage. 2010; 39(5): 831–838.
  70. Gift AG, Moore T, Soeken K. Relaxation to reduce dyspnea and anxiety in COPD patients. Nurs Res. 1988; 17: 408–413.
  71. Thompson E, Solà I, Subirana M, et al. Non-invasive interventions for improving well-being and quality of life in patients with lung cancer. Cochrane Database Syst Rev. 2004; 50(4): CD004282.
  72. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003; 58(4): 339–343.
  73. Kelsall A, Decalmer S, Webster D, et al. How to quantify coughing: correlations with quality of life in chronic cough. Eur Respir J. 2008; 32(1): 175–179.
  74. Freestone C, Eccles R. Assessment of the antitussive efficacy of codeine in cough associated with common cold. J Pharm Pharmacol. 1997; 49(10): 1045–1049.
  75. Parvez L, Vaidya M, Sakhardande A, et al. Evaluation of antitussive agents in man. Pulm Pharmacol. 1996; 9(5-6): 299–308.
  76. Smith J, Owen E, Earis J, et al. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2006; 117(4): 831–835.
  77. Ramsay J, Wright C, Thompson R, et al. Assessment of antitussive efficacy of dextromethorphan in smoking related cough: objective vs. subjective measures. Br J Clin Pharmacol. 2008; 65(5): 737–741.
  78. Daviskas E, Anderson SD, Eberl S, et al. Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction. Respir Med. 2010; 104(11): 1645–1653.
  79. Wills P, Greenstone M, Wills P, et al. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev. 2001(2): CD002996.
  80. Kvale PA. Palliative care in lung cancer. Chest. 2007; 132: 368–403.
  81. Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest. 1974; 65(3): 299–306.
  82. Remiszewski P, Broniek A, Roszkowski K, et al. Rozlane krwawienia pęcherzykowe w przebiegu ziarniniakowatości Wegenera. Pneumonol Alergol Pol. 1996; 64: 71–77.
  83. Szopiński J, Kamiński Z, Bestry I, et al. [Pulmonary arteriovenous fistulas]. Pneumonol Alergol Pol. 1994; 62(11-12): 634–639.
  84. Plaza V, Serra-Batlles J, Falcó M, et al. [Have the causes of hemoptysis changed? An analysis of 213 patients undergoing fiber bronchoscopic exploration]. Arch Bronconeumol. 1995; 31(7): 323–327.
  85. Jougon J, Ballester M, Delcambre F, et al. Massive hemoptysis: what place for medical and surgical treatment. Eur J Cardiothorac Surg. 2002; 22(3): 345–351.
  86. Swanson KL, Johnson CM, Prakash UBS, et al. Bronchial artery embolization : experience with 54 patients. Chest. 2002; 121(3): 789–795.
  87. Antonelli M, Midulla F, Tancredi G, et al. Bronchial artery embolization for the management of nonmassive hemoptysis in cystic fibrosis. Chest. 2002; 121(3): 796–801.
  88. Senkus-Konefka E, Dziadziuszko R, Bednaruk-Młyński E, et al. A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC). Br J Cancer. 2005; 92(6): 1038–1045.
  89. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1992; 65(6): 934–941.
  90. Kelly JF, Delclos ME, Morice RC, et al. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience. Int J Radiat Oncol Biol Phys. 2000; 48(3): 697–702.
  91. Seto AH, Dunlap DS. Tranexamic acid in oncology. Ann Pharmacother. 1996; 30(7-8): 868–870.
  92. Gagnon B, Mancini I, Pereira J, et al. Palliative management of bleeding events in advanced cancer patients. J Palliat Care. 1998; 14(4): 50–54.
  93. Dean A, Tuffin P. Fibrinolytic inhibitors for cancer-associated bleeding problems. J Pain Symptom Manage. 1997; 13(1): 20–24.
  94. Dobrogowski J, Mayzner-Zawadzka E, Drobnik L, et al. Uśmierzanie bólu pooperacyjnego — zalecenia 2008. Ból. 2008: 9.
  95. Groeben H. Epidural anesthesia and pulmonary function. Journal of Anesthesia. 2006; 20(4): 290–299.
  96. Gruber EM, Tschernko EM. Anaesthesia and postoperative analgesia in older patients with chronic obstructive pulmonary disease: special considerations. Drugs Aging. 2003; 20(5): 347–360.
  97. Licker M, Schweizer A, Ellenberger C, et al. Perioperative medical management of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2007; 2(4): 493–515.
  98. Pergolizzi J, Boger RH, Budd K, et al. Opioidy i postępowanie w ciężkim bólu przewlekłym u osób starszych: konsensus międzynarodowego panelu ekspertów, ze szczególnym uwzględnieniem sześciu najczęściej stosowanych w praktyce klinicznej opioidów z III stopnia drabiny analgetycznej wg WHO (buprenorfina, fentanyl, hydromorfon, metadon, morfina, oksykodon). Onkol Prakt Klin. 2008; 4(supl. C).
  99. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007; 132(3): 237–251.
  100. Dobrogowski J, Przeklasa-Muszyńska A, Woroń J, et al. Zasady kojarzenia leków terapii bólu. Med Pal Prakt. 2007; 1: 6–15.
  101. Wordliczek J, Dobrogowski J. Leczenie bólu. Wydawnictwo Lekarskie PZWL, Warszawa 2011.
  102. Zajączkowska R, Krajnik M, Woroń J, et al. Leczenie bólu u pacjentów z terminalną niewydolnością narządową. Terapia. 2011; 10: 19–30.
  103. Dobrogowski J, Krajnik M, Jassem J, et al. Stanowisko dotyczące postępowania przeciwbólowego u chorych na nowotwory. Onkol Prakt Klin. 2009; 2: 55–68.
  104. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: cancer and treatment related anemia, version 1.2009. Search under “Guidelines for supportive care”.
  105. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999; 85(5): 1186–1196.
  106. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol. 1997; 34(3 Suppl 2): 4–12.
  107. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000; 5(5): 353–360.
  108. De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, et al. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004; 21(2): 127–136.
  109. Roscoe JA, Morrow GR, Hickok JT, et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer. 2002; 10(4): 329–336.
  110. Tchekmedyian NS, Kallich J, McDermott A, et al. The relationship between psychologic distress and cancer-related fatigue. Cancer. 2003; 98(1): 198–203.
  111. Jacobsen PB, Donovan KA, Weitzner MA. Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsychiatry. 2003; 8(4): 229–240.
  112. Visser MR, Smets EM. Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer. 1998; 6(2): 101–108.
  113. Bruera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol. 2003; 21(23): 4439–4443.
  114. Minton O, Richardson A, Sharpe M, et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. 2008; 100(16): 1155–1166.
  115. Spathis A, Dhillan R, Booden D, et al. Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med. 2009; 23(4): 325–331.
  116. Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010; 116(14): 3513–3520.
  117. Morrow GR, Hickok JT, Roscoe JA, et al. University of Rochester Cancer Center Community Clinical Oncology Program. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003; 21(24): 4635–4641.
  118. Stockler MR, O'Connell R, Nowak AK, et al. Zoloft's Effects on Symptoms and survival Time Trial Group. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol. 2007; 8(7): 603–612.
  119. Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomised double-blind study. Cancer Treat Rep. 1985; 69: 751–754.
  120. Bruera E, El Osta B, Valero V, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2007; 25(23): 3475–3481.
  121. Barsevick AM, Dudley WN, Beck SL, et al. A randomized clinical trial of energy conservation for patients with cancer-related fatigue. Cancer. 2004; 100(6): 1302–1310.
  122. Pietras T, Witusik A, Panek M, et al. Lęk i depresja u chorych na choroby obturacyjne płuc. Pol Merk Lek. 2009; 26: 631–635.
  123. Janssen DJA, Spruit MA, Leue C, et al. Ciro network. Symptoms of anxiety and depression in COPD patients entering pulmonary rehabilitation. Chron Respir Dis. 2010; 7(3): 147–157.
  124. Mulrow CD, Williams JW, Gerety MB, et al. Case-finding instruments for depression in primary care settings. Ann Intern Med. 1995; 122(12): 913–921.
  125. Bailey P. The Dyspnea-Anxiety-Dyspnea Cycle—COPD Patients’ Stories of Breathlessness: “It’s Scary /When you Can’t Breathe”. Qualitative Health Research. 2004; 14(6): 760–778.
  126. Thomas S, Bausewein C, Higginson I, et al. Breathlessness in cancer patients - implications, management and challenges. Eur J Oncol Nurs. 2011; 15(5): 459–469.
  127. von Leupoldt A, Mertz C, Kegat S, et al. The impact of emotions on the sensory and affective dimension of perceived dyspnea. Psychophysiology. 2006; 43(4): 382–386.
  128. Ng TP, Niti M, Tan WC, et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007; 167(1): 60–67.
  129. Yohannes AM, Baldwin RC, Connolly MJ. Depression and anxiety in elderly patients with chronic obstructive pulmonary disease. Age Ageing. 2006; 35(5): 457–459.
  130. de Walden-Gałuszko K. Zaburzenia snu. In: Psychoonkologia w praktyce klinicznej. Wydawnictwo Lekarskie PZWL, Warszawa 2011: 38–42.
  131. Argyropoulou P, Patakas D, Koukou A, et al. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration. 1993; 60(4): 216–220.
  132. Singh NP, Despars JA, Stansbury DW, et al. Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety. Chest. 1993; 103(3): 800–804.
  133. de Voogd JN, Wempe JB, Koëter GH, et al. Depressive symptoms as predictors of mortality in patients with COPD. Chest. 2009; 135(3): 619–625.
  134. Ström K, Boman G, Pehrsson K, et al. Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. Eur Respir J. 1995; 8(3): 425–429.
  135. Lacasse Y, Beaudoin L, Rousseau L, et al. Randomized trial of paroxetine in end-stage COPD. Monaldi Arch Chest Dis. 2004; 61(3): 140–147.
  136. Eiser N, Harte R, Spiros K, et al. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD. 2005; 2(2): 233–241.
  137. Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005; 127(4): 1205–1211.
  138. Glennon C, Seskevich J. Relaxation technique to ease dyspnea: a tool for oncology nurses. Clin J Oncol Nurs. 2008; 12(2): 369–371.
  139. Effing T, Monninkhof EM, van der Valk PD, et al. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007(4): CD002990.
  140. Pierzchała W, Barczyk G, Górecka D, et al. Zalecenia skiego Towarzystwa Chorób Płuc rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc (POChP). Pneumonol Alergol Pol. 2010; 78: 318–347.
  141. Plywaczewski R, Sliwinski P, Nowinski A, et al. Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy. Chest. 2000; 117(3): 679–683.
  142. Skwarski K. Nocna hipoksemia i zaburzenia rytmu serca u chorych z przewlekłą obturacyjną chorobą płuc. Pol Arch Med Wewn. 1989; 81: 283–294.
  143. Sliwiński P, Lagosz M, Górecka D, et al. The adequacy of oxygenation in COPD patients undergoing long-term oxygen therapy assessed by pulse oximetry at home. Eur Respir J. 1994; 7(2): 274–278.
  144. Goldstein RS, Ramcharan V, Bowes G, et al. Effect of supplemental nocturnal oxygen on gas exchange in patients with severe obstructive lung disease. N Engl J Med. 1984; 310(7): 425–429.
  145. O'Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am J Respir Crit Care Med. 1997; 155(2): 530–535.
  146. Somfay A, Porszasz J, Lee SM, et al. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J. 2001; 18(1): 77–84.
  147. O'Donnell DE, D'Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163(4): 892–898.
  148. Nonoyama ML, Brooks D, Lacasse Y, et al. Oxygen therapy during exercise training in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007(2): CD005372.
  149. Bruera E, de Stoutz N, Velasco-Leiva A, et al. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet. 1993; 342(8862): 13–14.
  150. Booth S, Kelly MJ, Cox NP, et al. Does oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med. 1996; 153(5): 1515–1518.
  151. Schettino G, Altobelli N, Kacmarek R. Noninvasive positive pressure ventilation reverses acute respiratory failure in select “do-not-intubate” patients. Critical Care Medicine. 2005; 33(9): 1976–1982.
  152. Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet. 2010; 376(9743): 784–793.
  153. Liss HP, Grant BJ. The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1988; 137(6): 1285–1288.
  154. Chu CM, Chan VL, Wong IWY, et al. Noninvasive ventilation in patients with acute hypercapnic exacerbation of chronic obstructive pulmonary disease who refused endotracheal intubation. Crit Care Med. 2004; 32(2): 372–377.
  155. Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet. 1993; 341(8860): 1555–1557.
  156. Cuomo A, Delmastro M, Ceriana P, et al. Noninvasive mechanical ventilation as a palliative treatment of acute respiratory failure in patients with end-stage solid cancer. Palliat Med. 2004; 18(7): 602–610.
  157. Chronic obstructive pulmonary disease: non-invasive ventilation with bi-phasic positive airways pressure in the management of patients with acute type 2 respiratory failure. Royal College of Physicians, British Thoracic Society, Intensive Care Society.
  158. Concise Guidance to Good Practice series, No 11 London, 2008.
  159. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23(6): 932–946.
  160. Nava S, Sturani C, Hartl S, et al. European Respiratory Society Task Force on Ethics and decision-making in end stage lung disease. End-of-life decision-making in respiratory intermediate care units: a European survey. Eur Respir J. 2007; 30(1): 156–164.
  161. Krajewski R. w imieniu Roboczej Grupy ds. problemów Etycznych Końca Życia. Komentarz do definicji. Med Paliat Prakt. 2008; 2: 78.
  162. Nici L, Donner C, Wouters E, et al. ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006; 173(12): 1390–1413.
  163. Gigliotti F, Coli C, Bianchi R, et al. Arm exercise and hyperinflation in patients with COPD: effect of arm training. Chest. 2005; 128(3): 1225–1232.
  164. Mador MJ, Deniz O, Deniz O, et al. Effect of respiratory muscle endurance training in patients with COPD undergoing pulmonary rehabilitation. Chest. 2005; 128(3): 1216–1224.
  165. Lötters F, van Tol B, Kwakkel G, et al. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur Respir J. 2002; 20(3): 570–576.
  166. Troosters T, Casaburi R, Gosselink R, et al. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 172(1): 19–38.
  167. Foglio K, Bianchi L, Bruletti G, et al. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J. 1999; 13(1): 125–132.
  168. Foglio K, Bianchi L, Ambrosino N. Is it really useful to repeat outpatient pulmonary rehabilitation programs in patients with chronic airway obstruction? A 2-year controlled study. Chest. 2001; 119(6): 1696–1704.
  169. Kozu R, Senjyu H, Jenkins SC, et al. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration. 2010; 79: 454–460.
  170. Clini E, Foglio K, Bianchi L, et al. In-hospital short-term training program for patients with chronic airway obstruction. Chest. 2001; 120(5): 1500–1505.
  171. Plankeel JF, McMullen B, MacIntyre NR. Exercise outcomes after pulmonary rehabilitation depend on the initial mechanism of exercise limitation among non-oxygen-dependent COPD patients. Chest. 2005; 127(1): 110–116.
  172. Cote CG, Celli BR. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J. 2005; 26(4): 630–636.
  173. Bołoz W. Rezygnacja z uporczywej terapii jako realizacja praw człowieka umierającego. Med Paliat Prakt. 2008; 2: 79–85.
  174. Bołoz W, et al. Krajnik M., Adamczyk A. Definicja uporczywej terapii. Konsensus polskiej grupy roboczej do spraw problemów etycznych końca życia. Med Paliat Prakt. 2008; 2: 77–78.
  175. Kodeks etyki lekarskiej, art. 32. Naczelna Izba Lekarska. Warszawa, 2010.
  176. Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J. 2008; 32(3): 796–809.
  177. Skilbeck J, Mott L, Page H, et al. Palliative care in chronic obstructive airways disease: a needs assessment. Palliat Med. 1998; 12(4): 245–254.
  178. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax. 2000; 55(12): 1000–1006.
  179. Binnebesel J, Janowicz A, Krakowiak P, Paczkowska A. Pozamedyczne aspekty opieki paliatywno-hospicyjnej. Via Medica, Gdańsk 2010.
  180. Jones I, Kirby A, Ormiston P, et al. The needs of patients dying of chronic obstructive pulmonary disease in the community. Fam Pract. 2004; 21(3): 310–313.
  181. Habraken JM, van der Wal WM, Ter Riet G, et al. Health-related quality of life and functional status in end-stage COPD: a longitudinal study. Eur Respir J. 2011; 37(2): 280–288.
  182. Shaw RE, Cohen F, Doyle B, et al. The impact of denial and repressive style on information gain and rehabilitation outcomes in myocardial infarction patients. Psychosom Med. 1985; 47(3): 262–273.
  183. Janiszewska J. Dobra komunikacja warunkiem wsparcia psychicznego chorych umierających. Nowa Medycyna — Opieka Paliatywna. 2004; 2: 12–15.
  184. Gerstman S. Rozmowa i wywiad w psychologii. Wydawnictwo Nukowe PWN, Warszawa 1976.
  185. Krakowiak P. Zdążyć z prawdą. O sztuce komunikacji w hospicjum. Via Medica, Gdańsk 2006.
  186. Back AL, Curtis JR. Communicating bad news. West J Med. 2002; 176(3): 177–180.
  187. Detering KM, Hancock AD, Reade MC, et al. The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. BMJ. 2010; 340: c1345.
  188. Curtis JR, Engelberg R, Young JP, et al. Patient-physician communication about end-of-life care for patients with severe COPD. Eur Respir J. 2004; 24(2): 200–205.
  189. de Walden-Gałuszko K. Przekazywanie złych informacji. In: U kresu. Opieka psychopaliatywna, czyli jak pomóc choremu, rodzinie i personelowi medycznemu środkami psychologicznymi. Wydawnictwo Medyczne Makmed, Gdańsk 2000: 88–92.
  191. Jassem E, Kozielski J, Górecka D, et al. Integrated care for patients with advanced chronic obstructive pulmonary disease: a new approach to organization. Pol Arch Med Wewn. 2010; 120(10): 423–428.
  192. Coventry PA, Grande GE, Richards DA, et al. Prediction of appropriate timing of palliative care for older adults with non-malignant life-threatening disease: a systematic review. Age Ageing. 2005; 34(3): 218–227.
  193. Dean MM. End-of-life care for COPD patients. Prim Care Respir J. 2008; 17(1): 46–50.
  194. Downey L, Curtis JR, Lafferty WE, et al. The Quality of Dying and Death Questionnaire (QODD): empirical domains and theoretical perspectives. J Pain Symptom Manage. 2010; 39(1): 9–22.
  195. Zarządzenie Prezesa Narodowego Funduszu Zdrowia (nr 63/ /2009/DSOZ z dnia 2 listopada 2009 r. w sprawie określenia warunków zawierania i realizacji umów w rodzaju opieka paliatywna i hospicyjna.
  196. Radbruch L, Payne S, Zarząd EA. Raport dotyczący standardów i norm dla opieki hospicyjnej i paliatywnej w Europie: część 1. Zalecenia Europejskiego Towarzystwa opieki paliatywnej. Med. Paliat. Prakt. 2010; 4: 41–53.
  197. Krakowiak P, Modlińska A, Binnebesel J. Podręcznik koordynatora wolontariatu hospicyjnego. Via Medica, Gdańsk 2008.
  198. Radbruch L, Payne S, Zarząd EA. Raport dotyczący standardów i norm dla opieki hospicyjnej i paliatywnej w Europie: część 2. Zalecenia Europejskiego Towarzystwa opieki paliatywnej. . Med. Paliat. Prakt. 2010; 4: 54–65.
  199. Jagielski D, Graczyk M, Jagielska A, et al. Is there room for a palliative care support team in an emergency hospital ward? Analysis of the palliative care support team activity at the University Hospital, Bydgoszcz, in 2002–2006. Adv Palliat Med. 2008; 7: 55–60.
  200. Modlinska A. Formy wolontariatu hospicyjnego. Wolontariat medyczny. In: Krakowiak P, Modlinska A, Binnebesel J. ed. Podręcznik koordynatora wolontariatu hospicyjnego. Via Medica, Gdańsk 2008: 57–59.
  201. Patel I. Integrated respiratory care: what forms may it take and what are the benefits to patients. Breathe. 2010; 6: 253–259.
  202. Marciniuk DD, Goodridge D, Hernandez P, et al. Canadian Thoracic Society COPD Committee Dyspnea Expert Working Group. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011; 18(2): 69–78.
  203. Booth S, Bausewein C, Higginson I, et al. Pharmacological treatment of refractory breathlessness. Expert Rev Respir Med. 2009; 3(1): 21–36.
  204. Kapella MC, Larson JL, Patel MK, et al. Subjective fatigue, influencing variables, and consequences in chronic obstructive pulmonary disease. Nurs Res. 2006; 55(1): 10–17.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: